Scarica l'app Stockscreener
12.70
6.19%
0.74
Pre-mercato:
13.13
0.43
+3.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
Dyne Therapeutics (DYN) Target Price Adjusted by Oppenheimer | D - GuruFocus
Oppenheimer Adjusts Dyne Therapeutics Price Target to $34 From $60, Maintains Outperform Rating - marketscreener.com
Oppenheimer Sees Potential in Dyne Therapeutics (DYN) with Revised Price Target | DYN Stock News - GuruFocus
(DYN) Technical Data - news.stocktradersdaily.com
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 5.5% – Here’s What Happened - Defense World
Bank of America Corp DE Decreases Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Evercore ISI - Defense World
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World
Dyne Therapeutics (DYN) Receives Outperform Rating as Confidence Grows | DYN Stock News - GuruFocus
Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com
Ameriprise Financial Inc. Increases Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Deutsche Bank AG Has $1.67 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics Inc (DYN) Volatility Hits 6.09%: What Good Investors Need To Be Aware Of - Stocksregister
How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com
66,998 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by BNP Paribas Financial Markets - Defense World
Antibody Conjugate Oligonucleotide Market Research 2025-2035, Competitive Analysis of Key PlayersAvidity Biosciences, Dyne Therapeutics, Tallac Therapeutics, and AstraZenecaResearchAndMarkets.com - Bluefield Daily Telegraph
Dimensional Fund Advisors LP Sells 66,569 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Northern Trust Corp Increases Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
H.C. Wainwright cuts Dyne Therapeutics target to $38 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Dyne Therapeutics target to $38 - Investing.com
H.C. Wainwright Adjusts Price Target for Dyne Therapeutics (DYN) - GuruFocus
Dyne Therapeutics (DYN) Price Target Lowered by HC Wainwright & Co. | DYN Stock News - GuruFocus
Chardan Capital Reconfirms Buy Rating for Dyne Therapeutics (DYN - GuruFocus
RBC Cuts Price Target on Dyne Therapeutics to $30 From $36, Keeps Outperform, Speculative Risk - marketscreener.com
H.C. Wainwright Adjusts Price Target for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
Chardan Capital Reconfirms Buy Rating for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Dyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates - Nasdaq
Dyne (DYN) Eyes Accelerated Approval for Key Programs by 2026 | DYN Stock News - GuruFocus
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | DYN Stock News - GuruFocus
Dyne Therapeutics, Inc. SEC 10-Q Report - TradingView
Dyne Therapeutics, Inc. (NASDAQ:DYN) Stake Cut by Invesco Ltd. - Defense World
Wells Fargo & Company MN Raises Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Raymond James Financial Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Investors Who Lost Money on Dyne Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationDYN - ACCESS Newswire
Is Dyne Therapeutics Inc. (NASDAQ:DYN) the Most Promising Small-Cap Stock According to Analysts? - Insider Monkey
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy - Yahoo Finance
11 Most Promising Small-Cap Stocks According to Analysts - Insider Monkey
Dyne Therapeutics Gets EU Orphan Drug Status for Duchenne Treatment - marketscreener.com
Dyne Therapeutics stock rises on orphan drug status By Investing.com - Investing.com Canada
Dyne Therapeutics stock rises on orphan drug status - Investing.com
Dyne Therapeutics (DYN) Gains EU Orphan Drug Status for DYNE-251 - GuruFocus
Dyne Therapeutics Receives European Medicines Agency (EMA) Orpha - GuruFocus
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation For DYNE-251 In Duchenne Muscular Dystrophy - marketscreener.com
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy - The Manila Times
Dyne Therapeutics Receives European Medicines Agency (EMA) - GlobeNewswire
Breakthrough DMD Treatment DYNE-251 Wins Crucial EU Orphan Status as Phase 1/2 Trial Shows Promise - Stock Titan
Dyne Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.06m - simplywall.st
Biotech stocks jump as Makary outlines FDA vision, RBC comments By Investing.com - Investing.com India
Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):